Int J Thyroidol.  2019 Nov;12(2):97-104. 10.11106/ijt.2019.12.2.97.

Cancer Immunotherapy Related Endocrine Adverse Effects

Affiliations
  • 1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. yjparkmd@snu.ac.kr
  • 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Cancer immunotherapy has emerged as a promising therapy for a wide variety of tumors. Immune checkpoint inhibitors including anti cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1) monoclonal antibodies have proven to be especially effective in various advanced cancers. However, cancer the immunotherapy disturbs the immune system and may also cause immune related side effects (IRAE) distinguished from cytotoxic chemotherapy toxicity. Among them, endocrine IRAE has been reported with a higher incidence than other organ IRAE. We focus on the most relevant and new aspects related to endocrine IRAE due to cancer immunotherapy in this review.

Keyword

Programmed cell death receptor 1 (PD-1); Programmed cell death receptor ligand 1 (PD-L1); Cytotoxic T-lymphocyte-associated antigen 4; Immune related adverse effect (IRAE)

MeSH Terms

Antibodies, Monoclonal
CTLA-4 Antigen
Drug Therapy
Immune System
Immunotherapy*
Incidence
Antibodies, Monoclonal
CTLA-4 Antigen
Full Text Links
  • IJT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error